Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival

Journal of Biological Regulators and Homeostatic Agents

Volumn 24, Issue 4, 2010, Pages 403-411

  Mullol, Joaquim ^a,b,c   Callejas, F B ^a,c   Mendez Arancibia E ^a,c   Fuentes, M ^a,c   Alobid, I ^b,c   Martinez Anton A ^a,c   Valero, A ^b,c   Picado, C ^b,c   Roca Ferrer, J ^a,c  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Cytokines; Eosinophil; Epithelial cells; GM CSF; IL 6; IL 8; Inflammation; Montelukast; Nasal mucosa; Nasal polyp

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTATE DEHYDROGENASE; MONTELUKAST; TUMOR NECROSIS FACTOR ALPHA; ACETIC ACID DERIVATIVE; CYTOKINE; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; QUINOLINE DERIVATIVE;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFICACY; EOSINOPHIL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; MALE; NOSE MUCOSA; NOSE POLYP; PROTEIN EXPRESSION; TREATMENT RESPONSE; ANIMAL; BIOSYNTHESIS; CATTLE; DRUG EFFECT; EOSINOPHILIA; EPITHELIUM CELL; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RHINITIS;

BOVINAE;

ACETATES; ADULT; ANIMALS; CATTLE; CELL SURVIVAL; CYTOKINES; EOSINOPHILIA; EOSINOPHILS; EPITHELIAL CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; NASAL MUCOSA; NASAL POLYPS; QUINOLINES; RHINITIS;

EID: 79952279016     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008; 63:8-160.
2. Fokkens W, Lund VJ, Mullol J. European Position Paper on Rhinosinusitis and Nasal Polyps 2007. Rhinology 2007; 20:1-136.
3. Bachert C, Gevaert P, Holtappels G, Cuvelier C, van Cauwenberge P. Nasal polyposis: from cytokines to growth. Am J Rhinol 2000; 14:279-90.
4. Denburg JA, Keith PK. Eosinophil Progenitors in Airway Diseases. Chest 2008; 134:1037-43.
5. Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001; 344:30-7. (Pubitemid 32064843)
6. Mullol J, Xaubet A, Gaya A, Roca-Ferrer J, López E, Fernàndez JC, Fernàndez MD, Picado C. Cytokine gene expression and release from epithelial cells. A comparison study between healthy nasal mucosa and nasal polyps. Clin Exp Allergy 1995; 25:607-15.
7. Mullol J, Xaubet A, López E, Roca-Ferrer J, Picado C. Comparative study of the effects of different glucocorticosteroids on eosinophil survival primed by cultured epithelial cell supernatants obtained from nasal mucosa and nasal polyps. Thorax 1995; 50:270-4.
8. Mullol J, López E, Roca-Ferrer J, et al. Effects of topical antiinflammatory drugs on eosinophil survival primed by epithelial cells: additive effect of glucocorticoids and nedocromil sodium. Clin Exp Allergy 1997; 27:1432-41. (Pubitemid 28005242)
9. Mullol J, Roca-Ferrer J, Xaubet A, Traserra J, Picado C. Inhibition of GM-CSF secretion by topical corticosteroids and nedocromil sodium. A comparison study using nasal polyp epithelial cells. Respir Med 2000; 94:428-31. (Pubitemid 30352998)
10. Mullol J, Roca-Ferrer J, Alobid I, Pujols L, Valero A, Xaubet A, Bernal-Sprekelsen M, Picado C. Effect of desloratadine on epithelial cell granulocyte-macrophage colonystimulating factor secretion and eosinophil survival. Clin Exp Allergy 2006; 36:52-8.
11. Scadding GK, Durham SR, Mirakian R, Jones NS, Drake-Lee AB, Ryan D, Dixon TA, Huber PAJ, Nasser SM. BSACI guidelines for the management of rhinosinusitis and nasal polyposis. Clin Exper Allerg 2007; 38:260-75.
12. Roca-Ferrer J, Mullol J, Lopez E, et al. Effect of topical antiinflammatory drugs on epithelial cell-induced eosinophil survival and GM-CSF secretion. Eur Respir J 1997; 10:1489-95. (Pubitemid 27311060)
13. Xaubet A, Mullol J, Roca-Ferrer J, et al. Effect on budesonide and nedocromil sodium on IL-8 and IL-6 release from human nasal mucosa and polyp epithelial cells. Respir Med 2001; 95:408-14. (Pubitemid 32624488)
14. Arnold R, Rihoux J, Konig W. Cetirizine counter-regulates interleukin-8 release from human epithelial cells (A549). Clin Exp Allergy 1999; 29:1681-91. (Pubitemid 30012427)
15. Carayol N, Crampette L, Mainprice B, et al. Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine. Allergy 2002; 57:1067-70. (Pubitemid 35238646)
16. Crampette L, Mainprice B, Bloom M, Bousquet J, Campbell AM. Inhibition of mediator and cytokine release from dispersed nasal polyp cells by terfenadine. Allergy 1996; 51:346-9. (Pubitemid 26232830)
17. Agrawal DK, Berro A. Effect of desloratadine (DL) on the apoptosis of human blood eosinophils. Ann Allergy Asthma Immunol 2003; 90:100-1.
18. Becler K, Håkansson L, Rak S. Treatment of asthmatic patients with a cysteinyl leukotriene receptor-1 antagonist montelukast (Singulair), decreases the eosinophil survival-enhancing activity produced by peripheral blood mononuclear leukocytes in vitro. Allergy 2002; 57:1021-8. (Pubitemid 35238638)
19. Tahan F, Jazrawi E, Moodley T, Rovati GE, Adcock IM. Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappaB p65-associated histone acetyltransferase activity. Clin Exp Allergy 2008; 38:805-11. (Pubitemid 351550673)
20. Tohda Y, Nakahara H, Kubo H, Haraguchi R, Fukuoka M, Nakajima S. Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma. Clin Exp Allergy 1999; 29:1532-6. (Pubitemid 29519284)
21. Price DB, Swern A, Tozzi CA, et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006; 61:737-42. (Pubitemid 43801409)
22. Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med 2006; 100:1952-59. (Pubitemid 44490289)
23. Ragab S, Parikh A, Darby YC, Scadding GK. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy 2001; 31:1385-91. (Pubitemid 32823875)
24. Parnes SM, Chuma AV. Acute effects of antileukotrienes on sinonasal polyposis and sinusitis. Ear Nose Throat J 2000; 79:18-20.
25. Andersson K, Shebani EB, Makeeva N, Roomans GM, Servetnyk Z. Corticosteroids and Montelukast: effects on airway epithelial and human umbilical vein endothelial cells. Lung 2010; 188:209-16.
26. Yang YF, Hsu JY, Fu LS, Weng YS, Chu JJ. Asthma drugs counter-regulate interleukin-8 release stimulated by sodium sulfite in an A549 cell line. J Asthma 2009; 46:238-43.
27. Altman GB, Altman LC, Luchtel DL, Jabbour AJ, Baker C. Release of RANTES from nasal and bronchial epithelial cells. Cell Biology and Toxicology 1997; 13:205-13. (Pubitemid 27135263)
28. Ichiyama T, Hasegawa S, Umeda M, Terai K, Matsubara T, Furukawa S. Pranlukast inhibits NF-kappa B activation in human monocytes/macrophages and T cells. Clin Exp Allergy 2003; 33:802-7. (Pubitemid 36760513)
29. Maeba S, Ichiyama T, Ueno Y, Makata H, Matsubara T, Furukawa S. Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules. Ann Allergy Asthma Immunol 2005; 94:670-4. (Pubitemid 40847154)
30. Linden, M. et al. Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis. Allergy 1999; 54:212-9. (Pubitemid 29185281)
31. Min YG, Lee KS. The role of cytokines in rhinosinusitis. J Korean Med Sci 2000; 15:255-9.
32. Robinson AJ, Kashanin D, O'Dowd F, Williams V, Walsh GM. Montelukast inhibition of resting and GM-CSF-stimulated eosinophil adhesion to VCAM-1 under flow conditions appears independent of cysLT(1)R antagonism. J Leukoc Biol 2008; 83:1522-9. (Pubitemid 351960334)
33. Braccioni F, Dorman SC, O'byrne PM, Inman MD, Denburg JA, Parameswaran K, Baatjes AJ, Foley R, Gauvreau GM. The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. J Allergy Clin Immunol 2002; 110:96-101. (Pubitemid 36132734)
34. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet LP, Wei LX, Efthimiadis AE, Zhang J, Hargreave FE. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999; 14:12-8. (Pubitemid 29411228)
35. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158:1213-20.